Today in after-hours trade, shares of Athersys (ATHX) were up 21% after the company announced positive phase 2 results for its Stroke trial. The phase 2 trial had two different parts. One part had a small dose selection phase of 16 patients in two cohorts, and the other part had 118 patients in the efficacy phase.
Patients were either given Athersys' Multi-stem cell therapy intravenously or received a placebo compound instead. The trial recruited patients with a type of stroke known as Ischemic stroke -- obstruction of blood going to the brain causing damage. This data presented today was a one-year followup of these patients who had improved in outcome.
The Multistem therapy performed better than the placebo compound. For the 65 patients that took Multistem Cell therapy about 23% of them achieved an excellent outcome score at the one year mark, on the other hand about 8% of the placebo patients achieved an excellent outcome score. This difference means that the Multistem cell therapy was statistically significant compared to the placebo group.
Comments
Log in or sign up to join the conversation.